Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With 5-0 Winning Streak, Bayer And J&J Move To Eliminate Remaining Xarelto Litigation

Executive Summary

Firms want Fifth Circuit to review whether federal law preempts failure-to-warn and design-defect claims; ruling in their favor could end 20,000-plus pending US cases.

You may also be interested in...



After 5-Year Winning Streak, Xarelto Makers Settle Personal Injury Suits

Bayer and Johnson & Johnson agree to resolve approximately 25,000 claims in federal and state courts for $775m, almost 13% of Xarelto's 2018 sales.

Product Liability Returning To Supreme Court With Government, Former FDA Officials On Opposite Sides

US government supports Merck, saying FDA labeling decision preempts Fosamax failure-to-warn claim. Joshua Sharfstein and two other former FDAers argue Merck sought warning on a lesser injury.

Liabilities Update: AbbVie Wins AndroGel Re-Trial; Actavis To Settle Out Of Testosterone MDL

For second time, judge finds problem with jury verdict against AbbVie; Bayer withdraws its appeal of Xarelto pre-trial rulings pending outcome of Supreme Court case.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123352

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel